Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Trevi Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
14.1
19.3
22.3
23
19.8
23.7
39.4
33.5
General and administrative
4.34
7.31
10.2
9.49
10.1
10.2
12.1
15.9
Operating expenses
18.4
26.6
32.5
32.5
29.9
33.9
51.5
49.3
Operating income
-18.4
-26.6
-32.5
-32.5
-29.9
-33.9
-51.5
-49.3
Interest expense
0.17
0.46
1.2
1.16
0.39
0
0
Interest income
4.75
3.6
6.54
Other non-operating income
-2.26
0.58
-0.29
-1.49
0.72
4.83
3.58
6.51
Pre-tax income
-20.7
-26.1
-32.8
-34
-29.2
-29.1
-47.9
-42.8
Income tax
-0.12
-0.02
-0.02
-0.02
-0.04
-0.03
-0.03
-0.06
Net income
-20.5
-26.1
-32.8
-33.9
-29.2
-29.1
-47.9
-42.8
EBITDA
-18.4
-26.6
-32.4
-32.4
-29.9
-33.8
-51.4
-49.2
EPS, basic
-58.44
-2.28
-1.81
-1.49
-0.45
-0.29
-0.47
-0.32
EPS, diluted
-58.44
-2.28
-1.81
-1.49
-0.45
-0.29
-0.47
-0.32
Shares, basic (weighted)
0.44
11.7
18.1
22.8
64.5
99
102
135
Shares, diluted (weighted)
0.44
11.7
18.1
22.8
64.5
99
102
135
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
7.2
57.3
45
36.8
12.6
32.4
34.1
18.9
Short-term investments
108
50.6
73.5
169
Other current assets
1.44
1.68
0.27
0.24
1.31
0.96
0.87
2.13
Total current assets
8.82
59.6
46.3
38
123
87.5
109
192
Property, plant and equipment
0.15
0.12
0.1
0.05
0.17
0.22
0.16
0.18
Lease right-of-use assets
0.31
0.23
0.13
0.02
1.14
0.92
0.68
Other non-current assets
0.53
0.33
0.21
0.3
0.24
0.93
Total assets
10.5
60
47.1
38.5
123
89.4
111
193
Accounts payable
0.6
1.6
2.02
2.85
2.86
1.81
3.41
3.91
Accrued liabilities
2.07
3.5
3.43
3.81
3.52
3.71
6.81
5.53
Total current liabilities
2.68
5.2
5.56
12.7
13.4
5.82
10.5
9.75
Lease liabilities
0.05
0.26
0.14
0.02
0
1
0.75
0.45
Other non-current liabilities
0
Total liabilities
120
5.46
19.8
21.4
15.6
6.86
11.3
10.2
Paid-in capital
169
174
198
318
322
387
513
Retained earnings
-109
-114
-147
-181
-210
-239
-287
-330
Other comprehensive income
-0.12
-0.03
0.06
0.15
Shareholders' equity
-109
54.5
27.3
17.1
107
82.5
99.6
183
Total equity
-109
54.5
27.3
17.1
107
82.5
99.6
183
Total liabilities and equity
10.5
60
47.1
38.5
123
89.4
111
193
Shares outstanding
0.44
17.8
18.5
28.5
59.9
68.3
93.6
128
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-20.5
-26.1
-32.8
-33.9
-29.2
-29.1
-47.9
-42.8
Depreciation and amortization
0.02
0.04
0.05
0.05
0.04
0.12
0.15
0.14
Stock-based compensation
0.5
1.13
2.42
2.54
2.33
2.25
3.59
5.19
Change in receivables
-0.14
-0.37
Change in payables
0.07
0.78
0.42
0.83
0.01
-1.05
1.61
-0.6
Cash from operations
-18.3
-23.1
-29
-28.9
-28.2
-31.7
-38.3
-42.1
Capital expenditures
-0.16
-0.01
-0.03
-0.16
-0.14
-0.04
-0.01
Purchases of investments
-126
-9.93
-98.5
-171
Sales and maturities of investments
19
69.5
77
76.6
Cash from investing
-0.16
-0.01
-0.03
-107
59.4
-21.5
-94.1
Debt issued
14
Debt repaid
-4.81
-5.83
Stock issued
0.01
0.04
0.03
0.14
0.07
0.39
2.08
Cash from financing
3.63
73.2
16.7
20.8
111
-7.91
61.5
121
Net change in cash
-14.8
50.1
-12.3
-8.17
-24.2
19.8
1.7
-15.2
Free cash flow
-18.4
-23.1
-29
-28.3
-31.8
-38.3
-42.1
Interest paid
0.15
0.18
0.6
0.59
0.33
0
Income taxes paid
-0.03
-0.03
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $14.41 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-15.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-15.5%
Net income / average total assets.
Return on invested capital (ROIC)
-17.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
83.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
19.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
46.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
74.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
16.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
32.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
32.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
27.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
49.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
37.3x
Current assets / current liabilities.
Quick ratio
36.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
36.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.34
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.34
Cash from operations / diluted weighted shares.
Book value per share
$2.26
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
6.39x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.39x
Market cap / tangible book value, when positive.
FCF yield
-2.6%
Free cash flow / market cap.
Earnings yield
-2.5%
Net income / market cap (the inverse of P/E).
Was Trevi Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $42.8M.
How much free cash flow did Trevi Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $42.1M minus capital expenditures of $12.0K left free cash flow of -$42.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.